2,5-Dimethylimidazo<4,5-d>pyridazin-4-one | 76756-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,5-Dimethylimidazo<4,5-d>pyridazin-4-one
• 英文别名: 2,5-dimethyl-1H-imidazo[4,5-d]pyridazin-4-one
• CAS: 76756-59-7
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: IBZMUJGEKSWOKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,5-Dimethylimidazo<4,5-d>pyridazin-4-one 在 tetraphosphorus decasulfide 作用下， 以 various solvent(s) 为溶剂， 反应 6.5h， 以27.3%的产率得到2,5-Dimethylimidazo<4,5-d>pyridazine-4-thione
  参考文献：
  名称：

  Studies on the imidazo[4,5-d]pyridazine ring system. Course of alkylation of imidazo[4,5-d]pyridazine-4-thione

  摘要：

  DOI：

  10.1021/jo00325a008
• 作为产物：
  描述：

  4,5-Diamino-2-methyl-3(2H)-pyridazinone 以25%的产率得到
  参考文献：
  名称：

  CHEN SHIH-FONG; PANZICA R. P., J. ORG. CHEM., 1981, 46, NO 12, 2467-2473

  摘要：

  DOI：

文献信息

• [EN] 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS<br/>[FR] PYRAZOLES 3,4-DISUBSTITUTES SERVANT D'INHIBITEURS DE KINASES CYCLINES DEPENDANTES (CDK), OU DE KINASES AURORA OU DE GLYCOGENE SYNTASES 3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2006003440A1

  公开（公告）日：2006-01-12

  The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: Rq is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR5; X' is NR4', O, S or S(O); A is a bond or -(CH2)m-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group -(CH2)p- wherein p is 2 to 4; and R1 to R6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

  本发明提供式(I)的化合物；或其盐、溶剂化物或N-氧化物；其中：Rq选自基团(a)、(b)和(c)；星号表示与吡唑环的连接点；X为N或CR5；X'为NR4'、O、S或S(O)；A为键或-(CH2)m-(B)n-；B为C=O、NRg(C=O)或O(C=O)，其中Rg为氢或C1-4烃基，可选择性地被羟基或C1-4烷氧基取代；m为0、1或2；n为0或1；R0为氢，或与存在的NRg一起形成基团-(CH2)p-，其中p为2至4；R1至R6b如说明书中所定义。式(I)的化合物作为CDK、aurora和GSK-3激酶的抑制剂，对于治疗或预防由所述激酶介导的疾病，如癌症，具有用途。
• 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors
  申请人：Gill Liam Adrian

  公开号：US20080004270A1

  公开（公告）日：2008-01-03

  The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: R q is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR 5 ; X″ is NR 4 ; O, S or S(O); A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R 0 is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; and R 1 to R 6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

  本发明提供了式（I）的化合物；或其盐、溶剂或N-氧化物；其中：Rq选择自组（a）、（b）和（c）；星号表示与吡唑环的连接点；X为N或CR5；X″为NR4；O、S或S（O）；A为键或—（CH2）m—（B）n—；B为C═O、NRg（C═O）或O（C═O），其中Rg为氢或C1-4烃基，可选地被羟基或C1-4烷氧基取代；m为0、1或2；n为0或1；R0为氢或与NRg一起，形成—（CH2）p—基团，其中p为2至4；R1至R6如描述中所定义。式（I）的化合物具有作为CDK、极光激酶和GSK-3激酶抑制剂的活性，可用于治疗或预防由该激酶介导的癌症等疾病。
• Studies on the imidazo[4,5-d]pyridazine ring system. Course of alkylation of imidazo[4,5-d]pyridazine-4-thione
  作者：Shih-Fong Chen、Raymond P. Panzica

  DOI：10.1021/jo00325a008

  日期：1981.6
• CHEN SHIH-FONG; PANZICA R. P., J. ORG. CHEM., 1981, 46, NO 12, 2467-2473
  作者：CHEN SHIH-FONG、 PANZICA R. P.

  DOI：——

  日期：——